Phase II Trial Shows Antitumor Activity With Cemiplimab in mCSCC
Alexander D. Guminski, MD, PhD, discusses the 12-month follow-up data from a phase II study investigating the role of cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.
